Cheaper versions of Ozempic are set to change obesity care in India as semaglutide’s key patent lapses on 20 March, opening the way for local copies at about half the current cost and triggering a rush by hospitals, digital platforms and drugmakers to capture a fast-growing weight-loss drug market.
At least five Indian pharmaceutical firms, including Mankind Pharma Ltd., Ajanta Pharma Ltd., Sun Pharmaceutical Industries Ltd., Lupin Ltd. and Dr Reddy’s Laboratories Ltd., plan to introduce generic semaglutide soon after the patent expiry, according to company disclosures and earnings call comments, with weekly injections likely priced near 5,000 rupees, compared with significantly higher charges for Novo Nordisk A/S’s branded therapy.
generic Ozempic India patent expiry and GLP-1 market outlook
Credit rating agency CareEdge Ratings estimated in a 10 March note that India’s GLP-1 drug market could climb from roughly 10 billion rupees in 2025 to as much as 50 billion rupees by 2030, projecting initial price drops of 40% to 50% after semaglutide loses protection and forecasting further reductions next year as more manufacturers launch competing products.
India follows Canada as the next major market where Novo Nordisk loses monopoly control over semaglutide, turning the country, with a large pool of people living with obesity and a strong generic industry, into a key test case for how low prices for anti-obesity injections might fall when multiple suppliers compete on similar products.
Metabolic illnesses tied to lifestyle, including thyroid disorders, diabetes and fatty liver disease, have risen sharply among India’s population of more than 1.4 billion, while calorie-dense diets rich in oil and fat, combined with limited physical activity in many cities, have helped push India to the third spot globally for overweight residents, behind the US and China.
generic Ozempic India demand from clinics, hospitals and telehealth
Endocrinologist Swati Pradhan, who runs the LiveLight Clinic in south Mumbai, currently sees about 12 obesity patients daily but expects that figure to at least double once generic semaglutide arrives, especially as more people can afford structured weight-loss plans than under existing prices for Novo Nordisk’s injections.
Pradhan charges between 21,000 rupees and 26,000 rupees a month for a supervised programme that combines diet counselling, regular blood investigations, management of side effects and weekly consultations, and said the approach often delivers weight reduction of up to five kilograms each month, results that some patients do not match when they use injections without ongoing medical guidance.
Pradhan observed that many people who initially skip formal supervision eventually seek help after early enthusiasm fades, saying those who exit too quickly often struggle with complications or slower progress, noting that individuals who leave the programme at the outset frequently “start seeing side effects or their weight loss slows down, and end up contacting the clinic,” after trying to manage treatment independently.
generic Ozempic India corporate, startup and hospital strategies
Large hospital chains are building dedicated services around the expected jump in demand, with Apollo Health & Lifestyle Ltd. and Fortis Healthcare Ltd. expanding or launching obesity management centres staffed by doctors, nutritionists, fitness trainers and mental health professionals; Apollo Clinics already hosts specialised obesity centres in collaboration with Novo Nordisk, and “The hospital chain continues to evaluate the weight management space given the large opportunity here,” Apollo Hospitals Enterprise Ltd.’s chief financial officer Krishnan Akhileswaran told Bloomberg News.
Diagnostic networks such as Tata 1MG Technologies Pvt. are advertising discounted obesity screening bundles, while online pharmacies including PharmEasy deliver semaglutide to homes after teleconsultations, although market research firm Pharmarack reports that e-commerce still makes up only a small fraction of total drug sales compared with India’s extensive offline chemist network.
Bengaluru-based software professional Cipun Mishra paid 65,000 rupees in May for a three-month package with app-based wellness company HealthifyMe Wellness Pvt., which included monthly access to an endocrinologist, round-the-clock support from fitness and diet coaches, weight-loss vials and a supervised monthly injection; Mishra has lost about 42 kilograms over 40 weeks of weekly injections and said the initial structure was “critical.”
generic Ozempic India patient support programmes and regulation
Mishra said early weeks involved multiple behavioural shifts, explaining that “In the beginning, a lot of habitual changes” happen, such as daily weight checks, taking prescribed supplements and staying accountable to a support network, which Mishra described as “encouraging,” and added, “I took up this programme because I feared I was going to discontinue my journey,” without such external guidance.
Dr Reddy’s, one of India’s largest pharmaceutical companies, is in talks with hospitals and healthcare providers to introduce patient support programmes alongside its planned generic semaglutide launch, while Cipla Ltd., which sells Eli Lilly & Co.’s patented tirzepatide in India under the brand Yurpeak, is collaborating with obesity clinics in smaller towns, with Cipla’s Chief Executive Officer Designate Achin Gupta noting that health professionals are “very keen on how to prescribe, how to manage” this treatment category.
Consulting firm Alvarez & Marsal’s managing director for health care and life sciences, Kaustav Ganguli, told Bloomberg News that hospitals which bundle GLP-1 drugs with diagnostic services and long-term follow-up visits could earn up to 110 million rupees in yearly revenue per facility, compared with around 60 million rupees from a model focused mainly on medicine sales, and said that growth driven by patients starting generic therapy would directly benefit healthcare institutions.
generic Ozempic India regulations, global context and market data
India’s drug regulator has responded to rising interest in obesity treatments by banning advertising and promotional campaigns linked to weight-loss programmes, a policy that also covers disease-awareness drives, social media endorsements by influencers and corporate marketing efforts, in an attempt to limit aggressive commercial messaging while demand for semaglutide and similar drugs accelerates.
Startups are moving into the same space, with New Delhi-based Enlighten Now Healthcare Pvt., operator of the Elevate Now weight management platform, seeking partnerships with corporates, large gym chains and drugmakers including Dr Reddy’s, according to founder Suryansh Kumar; the company, which has about 30,000 registered patients, intends to open eight physical clinics during this year to complement online services.
Adoption patterns for obesity injections have varied around the world, with US growth helped by telehealth portals owned by Eli Lilly and Novo Nordisk and by insurance coverage and government-supported initiatives, while in China, online platforms such as JD Health feature prominently in distribution plans, but in India, where healthcare is mostly paid out-of-pocket, individuals bear most costs and therefore remain a central focus for hospitals and clinics designing long-term supervision packages.
Key figures on India’s semaglutide and GLP-1 landscape are summarised below.
| Aspect | Detail |
|---|---|
| Semaglutide patent expiry in India | 20 March |
| Expected weekly generic semaglutide price | Around 5,000 rupees |
| Estimated price drop post-expiry | 40%–50%, with further cuts next year |
| India GLP-1 market size 2025 | 10 billion rupees |
| Projected GLP-1 market size 2030 | Up to 50 billion rupees |
| Potential annual revenue per obesity-focused hospital | Up to 110 million rupees |
Cipla’s Achin Gupta said that “India as a market is very deep, and what we are discovering is that therapies have takers in different parts of the country,” a view shared by many industry participants as they prepare for a surge in demand once generic semaglutide appears, with hospitals, startups, diagnostic chains and telehealth platforms all positioning themselves to capture patients seeking structured, long-term obesity care.
